Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More Barriers To Entry For M&A In China? Novartis Case Provides Some Clarity

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Much awaited regulations on how China will review inbound mergers and acquisitions in light of national security and competition suggest long waits for pending and future deals and new barriers to entry, say some business groups

You may also be interested in...



EU Chamber Of Commerce Urges Bold Reforms On Market Access By China’s New Leaders

The European Chamber of Commerce in China calls on Beijing to break the grip of state-owned companies on market access and seize a “historic opportunity” of a leadership transition to open the economy.

Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition

With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.

Nestle To Become No. 1 In China's Infant Formula Market Following Pfizer Nutrition Acquisition

With roughly 60% of Pfizer Nutrition sales coming from Asia, and 47% of that from China, Nestle slips into No. 1 spot in China’s infant formula market.

Related Content

UsernamePublicRestriction

Register

LL1132440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel